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Pharmacology, Therapeutics and Toxicology Unit, Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UKThe POP Trial Investigators read with interest this letter from Dr. No patient in this trial developed diarrhoea.
Karlsson [1] regarding the results of our Phase 1 trial [2]. We agree
that all safety information from this trial is important for our planning
of future trials.
The frequency of gastrointestinal adverse events and serious adverse
events in the 4 different treatment groups is already presented in Sup-
plementary Table 2 [2]. These adverse events were nausea, vomiting
or abdominal pain – all symptoms that are common after a paracetamol
overdose treated with acetylcysteine.DOIs of original article: https://doi.org/10.1016/j.ebiom.2019.07.013, https://doi.org/
10.1016/j.ebiom.2019.08.038.
E-mail address: james.dear@ed.ac.uk.
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